Condition: Endometrial Cancer · p53abn · Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
The RAINBO program is a studies group which proposes personalized treatment of patients suffering from endometrial cancer according to their molecular profile. the RAINBO-RED study allows observation or maintenance treatment with targeted therapy for one year (olaparib). This after standard therapy. The goal is to improve recurrence-free survival of patients treated with Olaparib.
This description comes directly from the study's public registry record.
Alexandra Leary, MD, PhD · +33 1 42 11 42 11 · Alexandra.LEARY@gustaveroussy.fr
Flora NGADJEUA TCHOUATIEU, PhD · +33 1 42 11 42 11 · Flora.NGADJEUA-TCHOUATIEU@gustaveroussy.fr
Always discuss trial participation with your own doctor first.
| Centre Hospitalier D'Albi | Albi, France | Recruiting |
| Institut Cancerologie de L'Ouest-Angers | Angers, France | Recruiting |
| Chu Besancon | Besançon, France | Recruiting |
| Centre Hospitalier de Carcassonne | Carcassonne, France | Recruiting |
| Chu Dijon | Dijon, France | Recruiting |
| Groupe Hospitalier Mutualiste de Grenoble | Grenoble, France | Not Yet Recruiting |
| CHU De LIMOGES | Limoges, France | Recruiting |
| Centre LEON BERARD | Lyon, France | Recruiting |
| Institut Paoli Calmettes | Marseille, France | Recruiting |
| Centre Antoine LACASSAGNE | Nice, France | Recruiting |
| Institut Marie-Curie | Paris, France | Recruiting |
| Hopital Cochin | Paris, France | Not Yet Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06712472